Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up – Time to Buy?

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares gapped up prior to trading on Tuesday . The stock had previously closed at $72.08, but opened at $75.24. Zealand Pharma A/S shares last traded at $75.24, with a volume of 1,000 shares.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a research report on Tuesday, December 16th. Zacks Research raised shares of Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a report on Monday, September 15th. Finally, BTIG Research raised shares of Zealand Pharma A/S to a “strong-buy” rating in a research note on Friday, November 28th. Six analysts have rated the stock with a Strong Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Strong Buy”.

Zealand Pharma A/S Trading Up 0.9%

The company has a debt-to-equity ratio of 0.02, a current ratio of 14.10 and a quick ratio of 14.10. The firm’s 50 day moving average is $76.33 and its 200 day moving average is $68.21. The company has a market capitalization of $5.34 billion, a PE ratio of 5.41 and a beta of 0.72.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.90) earnings per share for the quarter, beating the consensus estimate of ($1.11) by $0.21. The business had revenue of $7.76 million during the quarter, compared to analysts’ expectations of $4.54 million. Zealand Pharma A/S had a net margin of 71.79% and a return on equity of 55.76%. As a group, equities analysts predict that Zealand Pharma A/S will post -2.19 EPS for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.